Teduglutide (Revestive, Nycomed/Takeda, in the European Union; Gattex, NPS Pharmaceuticals, in the United States) appears to reduce the need for parenteral support in patients with short bowel ...
Please provide your email address to receive an email when new articles are posted on . Use of teduglutide for short bowel syndrome did not increase incidence of GI malignancies. The results support ...
Discover comprehensive details about Teduglutide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2 ...
Review the side-effects of Teduglutide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Please provide your email address to receive an email when new articles are posted on . Patients treated with teduglutide had significant reductions in parenteral nutrition/IV fluid needs over 10 ...
BEDMINSTER, N.J., Jan 31, 2011 (BUSINESS WIRE) -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and ...
FDA Approves Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowe
BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (NAS: NPSP) , a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases ...
There is a simple discount patient access scheme for teduglutide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
The US Food and Drug Administration (FDA) today approved teduglutide (Gattex, NPS Pharmaceuticals) to treat the estimated 10,000 to 15,000 American adults with short bowel syndrome (SBS). Teduglutide, ...
1.1 Teduglutide is recommended, within its marketing authorisation, as an option for treating short bowel syndrome (SBS) in people 1 year and above. People's condition should be stable following a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results